EVL.F - Evolus, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
11.55
-0.16 (-1.37%)
As of 4:37PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close11.71
Open11.68
Bid11.99 x 0
Ask12.05 x 0
Day's Range11.55 - 11.68
52 Week Range9.46 - 27.63
Volume100
Avg. Volume83
Market Cap325.798M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Evolus, Inc. (EOLS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Evolus, Inc. (EOLS) Q1 2019 Earnings Call Transcript

    EOLS earnings call for the period ending March 31, 2019.

  • Benzinga2 months ago

    3 Stocks To Watch Ahead Of Earnings

    These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday.  The performance beauty ...

  • 3 Small-Cap Biotech Stocks to Watch Now
    Motley Fool3 months ago

    3 Small-Cap Biotech Stocks to Watch Now

    These under-the-radar stocks could be poised to make big moves in the coming months.

  • Why Penn Virginia, Evolus, and Cousins Properties Slumped Today
    Motley Fool3 months ago

    Why Penn Virginia, Evolus, and Cousins Properties Slumped Today

    Merger and acquisition moves played a role in the declines for two of these stocks.

  • Why Evolus Stock Is Soaring 12% Higher Today
    Motley Fool3 months ago

    Why Evolus Stock Is Soaring 12% Higher Today

    There are no frown lines from investors as the company is about to launch a competitor to Botox.

  • TheStreet.com4 months ago

    Evolus Stockholders May Be Frowning in the Short Run

    In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with David Moatazedi, president and CEO of Evolus Inc. with a new drug to compete with Botox. Shares of EOLS have surged from $16 to $29 after the company received FDA approval on Friday.

  • CNBC4 months ago

    Cramer Remix: If the market drops tomorrow, buy this stock

    Jim Cramer explains why Cisco could be a winner if the market heads lower.

  • Why Leggett & Platt, Mueller Industries, and Evolus Jumped Today
    Motley Fool5 months ago

    Why Leggett & Platt, Mueller Industries, and Evolus Jumped Today

    These stocks helped lead Wall Street higher.

  • TheStreet.com5 months ago

    Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

    Billionaire David Tepper, president of hedge fund Appaloosa LP, fired off a letter Tuesday demanding the Dublin-based pharmaceutical firm separate the roles of chairman and CEO. Following the release of the letter, Allergan's stock fell 0.4% Tuesday to close at $138.01. "The Board of Directors is committed to strong governance practices and independent board leadership," Allergan said in its statement.

  • Associated Press5 months ago

    Papa John's, Evolus rise; Gannett, Allergan slip

    Stocks that moved substantially or traded heavily on Monday: Papa John's International Inc., up $ 3.46 to $41.97 The head of the investment firm Starboard Value is being named board chairman at the troubled ...

  • TheStreet.com5 months ago

    Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

    shares fell almost 4% and Evolus Inc. shares gained almost 12% Monday after the U.S. Food and Drug Administration approved Evolus's new wrinkle treatment for adult patients which is expected to rival Allergan's Botox. The treatment, called Jeuveau, received FDA approval late Friday, some eight months after the agency first rejected the application citing deficiencies in its manufacturing and chemical composition.

  • Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings
    Investor's Business Daily5 months ago

    Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings

    Drug makers were active Monday, led by Alexion and Bristol-Myers Squibb, as stocks opened mixed and the Dow Jones industrials dug in to hold 25,000.

  • Reuters5 months ago

    UPDATE 1-FDA approves cheaper Botox rival to treat frown lines (Feb.1)

    An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent after the bell. The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product. "We see Evolus' entry into this market as very disruptive," Evolus Chief Executive Officer David Moatazedi said in an interview prior to the FDA's decision.

  • Reuters5 months ago

    FDA approves cheaper Botox rival to treat frown lines

    The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product. "We see Evolus' entry into this market as very disruptive," Evolus Chief Executive Officer David Moatazedi said in an interview prior to the FDA's decision. Evolus expects Jeuveau to be priced between 20 and 25 percent lower than Botox and is likely to be available throughout the United States at physician offices starting Spring 2019, the company said.

  • Maker of Botox Rival Soars as Treatment May Win Approval By Spring
    Bloomberg10 months ago

    Maker of Botox Rival Soars as Treatment May Win Approval By Spring

    The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day. Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.

  • Benzinga11 months ago

    Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...

  • Benzinga11 months ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Aesthetics company behind latest Botox rival was 'designed' to compete with Botox: CEO
    CNBC Videos4 months ago

    Aesthetics company behind latest Botox rival was 'designed' to compete with Botox: CEO

    Jim Cramer hears from Evolus President and CEO David Moatazedi about his company's cheaper rival to Allergan's Botox.